The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Saved in:
| Title: | The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. |
|---|---|
| Authors: | Hormaechea-Agulla D; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; CIBERobn, Córdoba, Spain.; ceiA3, Córdoba, Spain., Gahete MD; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; CIBERobn, Córdoba, Spain.; ceiA3, Córdoba, Spain., Jiménez-Vacas JM; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; CIBERobn, Córdoba, Spain.; ceiA3, Córdoba, Spain., Gómez-Gómez E; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; Urology Service, HURS/IMIBIC, Córdoba, Spain., Ibáñez-Costa A; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; CIBERobn, Córdoba, Spain.; ceiA3, Córdoba, Spain., L-López F; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; CIBERobn, Córdoba, Spain.; ceiA3, Córdoba, Spain., Rivero-Cortés E; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; CIBERobn, Córdoba, Spain.; ceiA3, Córdoba, Spain., Sarmento-Cabral A; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; CIBERobn, Córdoba, Spain.; ceiA3, Córdoba, Spain., Valero-Rosa J; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; Urology Service, HURS/IMIBIC, Córdoba, Spain., Carrasco-Valiente J; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; Urology Service, HURS/IMIBIC, Córdoba, Spain., Sánchez-Sánchez R; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; Anatomical Pathology Service, HURS/IMIBIC, Córdoba, Spain., Ortega-Salas R; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; Anatomical Pathology Service, HURS/IMIBIC, Córdoba, Spain., Moreno MM; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; Anatomical Pathology Service, HURS/IMIBIC, Córdoba, Spain., Tsomaia N; IPSEN Bioscience, Cambridge, MA, USA., Swanson SM; School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA., Culler MD; IPSEN Bioscience, Cambridge, MA, USA., Requena MJ; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.; Reina Sofia University Hospital (HURS), Córdoba, Spain.; Urology Service, HURS/IMIBIC, Córdoba, Spain., Castaño JP; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain. justo@uco.es.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain. justo@uco.es.; Reina Sofia University Hospital (HURS), Córdoba, Spain. justo@uco.es.; CIBERobn, Córdoba, Spain. justo@uco.es.; ceiA3, Córdoba, Spain. justo@uco.es., Luque RM; Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain. bc2luhur@uco.es.; Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain. bc2luhur@uco.es.; Reina Sofia University Hospital (HURS), Córdoba, Spain. bc2luhur@uco.es.; CIBERobn, Córdoba, Spain. bc2luhur@uco.es.; ceiA3, Córdoba, Spain. bc2luhur@uco.es. |
| Source: | Molecular cancer [Mol Cancer] 2017 Aug 29; Vol. 16 (1), pp. 146. Date of Electronic Publication: 2017 Aug 29. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
